RxDoctor Payments Data

Thomas Davis, MD

Neurology · Nashville, TNNPI 1821109893

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,331 of the $14,903 with a category attached, or 89.5%. AbbVie accounts for 97.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $5,378 and has fallen 65.4% since, to $1,862 in 2024.

$14,903in general payments, 2019–2025

Across 23 payments — averaging $647.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Acadia Pharmaceuticals Inc$252
  • Abbott$202
$76,788in research payments, 2019–2025

Across 107 payments — averaging $717.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ipsen Biopharmaceuticals, Inc$37K
  • UCB SA$23K
  • MDD US Operations, LLC$17K

What the payments were for

  • Consulting fees$13,33189%
  • Travel & lodging$8155%
  • Food & beverage$7575%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie20$14,450
Acadia Pharmaceuticals Inc2$252
Abbott1$202

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,903 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,800
Medicare patients
208
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate94$467,602
AustedoDeutetrabenazine38$287,572
IngrezzaValbenazine Tosylate26$194,319
Austedo XrDeutetrabenazine30$189,073
RytaryCarbidopa/Levodopa42$69,247
GocovriAmantadine Hcl15$59,273
Tetrabenazine20$58,099
NeuproRotigotine37$41,809
Carbidopa-LevodopaCarbidopa/Levodopa458$29,782
Carbidopa-Levodopa ErCarbidopa/Levodopa187$14,924
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone51$14,087
AzilectRasagiline Mesylate12$13,014
Ropinirole ErRopinirole Hcl33$9,090
Entacapone27$7,656
ValiumDiazepam11$5,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$252$467,60294 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →